Neutropenic Enterocolitis: The Silent but Serious Threat in Leukemia Care

Neutropenic enterocolitis (NEC) is a severe inflammatory disease of the bowel that occurs in conjunction with neutropenia and poses a significant risk in morbidity and mortality for patients who are immunocompromised, especially those with malignancies undergoing chemotherapy due to blood cancer. The critical clinical features to note are a fever, abdominal pain, diarrhea, and lab results demonstrating profound neutropenia along with increased CRP levels. Thinning and increasing inflammation of the colon wall as well as other characteristic radiologic signs noticeable on CT imaging, are also important indicators. Diagnosis should be made at as early as possible using any of the previously mentioned signs. First, management primarily involves a conservative approach. In-hospital care of NEC includes bowel rest, fluid replacement therapy, wide-coverage antibiotics, and G-CSF to help speed up neutrophil emission. In contrast to these methods, surgery should only be done if the patient is more complex and has additional problems like leaks or worsened blood loss. This article discusses the case of a 27-year-old female with relapsing acute myeloid leukemia who developed NEC during chemotherapy and ultimately acheived favorable outcomes with conservative treatment. The collaborative approach provided prompt solutions that mitigated comprehensive damage by exploring every aspect of care, which this entity improved outcomes for newly diagnosed patients suffering from this condition.